Overview

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the corresponding loose combination under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Candesartan
Candesartan cilexetil
Nifedipine